Zobrazeno 61 - 70
of 1 548
pro vyhledávání: ''
Autor:
Akshata Udyavar, Junko Aimi, Ching-Wei Chang, Mark R. Lackner, Timothy R. Wilson, Heidi Savage, Jill M. Spoerke, Richard Bourgon, Anneleen Daemen, Joyce O'Shaughnessy
Publikováno v:
Molecular Cancer Research. 17:97-108
The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-posi
Autor:
Mohammed G. Ghonime, Kevin A. Cassady
Publikováno v:
Cancer Immunology Research. 6:1499-1510
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas resistant to most cancer treatments. Surgical resection remains the primary treatment, but this is often incomplete, ultimately resulting in high mortality and morb
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Tong Zhang, Gayatri Gowrishankar, Aileen Hoehne, Sanjiv S. Gambhir, Oliver D. K. Maddocks, Patrick McCormick, Erik Årstad, Adam J. Shuhendler, Mathias Berndt, Hannah E. Greenwood, Timothy H. Witney, Matthias Glaser, David Y. Lewis, Norman Koglin, Thibault Gendron, Kerstin Sander, Mark F. Lythgoe
Publikováno v:
McCormick, P, Greenwood, H E, Glaser, M, Maddocks, O D K, Gendron, T, Sander, K, Gowrishankar, G, Hoehne, A, Zhang, T, Shuhendler, A J, Lewis, D Y, Berndt, M, Koglin, N, Lythgoe, M, Gambhir, S S, Arstad, E & Witney, T 2019, ' Assessment of tumor redox status through (S)-4-(3-[ 18 F]fluoropropyl)-L-glutamic acid PET imaging of system x c activity ', Cancer Research, vol. 79, no. 4, 79, pp. 853-863 . https://doi.org/10.1158/0008-5472.CAN-18-2634
The cell's endogenous antioxidant system is vital to maintain redox homeostasis. Despite its central role in normal and pathophysiology, no noninvasive tools exist to measure this system in patients. The cystine/glutamate antiporter system xc− main
Autor:
Heidi M. Namløs, Tale Barøy, Else Munthe, Skyler Mishkin, Susanne Lorenz, Eva W. Stratford, Leonardo A. Meza-Zepeda, Kjetil Boye, Ola Myklebost, Brian Kudlow, Bodil Bjerkehagen
Publikováno v:
Molecular Cancer Therapeutics. 17:2473-2480
Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of KIT and PDGFRA mutations is
Autor:
Shinji Kohsaka, Masahito Kawazu, Kanju Saka, Shinya Kojima, Masaaki Nagano, Hirotaro Iwase, Hiroyuki Mano, Toshihide Ueno
Publikováno v:
Clinical Cancer Research. 24:5112-5122
Purpose: The advent of next-generation sequencing technologies has enabled the identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) among various cancers. However, the significance of infrequent mutations has no
Autor:
Raghu Kalluri, Valerie S. LeBleu, Yingqi Teng, Hans Petter Eikesdal, Julienne L. Carstens, Hikaru Sugimoto, Lisa M. Becker, Keizo Kanasaki, Akane Kizu
Publikováno v:
Molecular Cancer Research. 16:1568-1578
Deregulated transforming growth factor-β (TGFβ) signaling is a common feature of many epithelial cancers. Deletion of TGFβ receptor type 2 (TGFBR2) in fibroblast specific protein-1 (FSP1)-positive stromal cells induces squamous cell carcinoma in t
Autor:
Christine A. Pratilas, Sharmeen Uddin, Amy Allen, Zhan Yao, Jiawan Wang, Ira J. Dunkel, Barry S. Taylor, Neal Rosen, Philip Jonsson, Alice Can Ran Qin, Katia Manova, Sofia Haque, David J. Pisapia, Mary Petriccione, Marc K. Rosenblum
Publikováno v:
Cancer Discovery. 8:1130-1141
BRAFV600E hyperactivates ERK and signals as a RAF inhibitor–sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely chara
Autor:
Jennifer E. Hardingham, Amanda R. Townsend, Timothy J. Price, Sue Yeend, Pamela Cooper, Christos S. Karapetis, Niall C. Tebbutt, Rohit Joshi, Louise Pirc, Nimit Singhal
Publikováno v:
Clinical Cancer Research. 24:3838-3844
Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety and efficacy of the combination of irinotecan, panitumumab, and everolimus.
Autor:
Rebecca Boiarsky, Kevin S. Kapner, Daniel Zhao, Stephanie W. Cheng, Ananya D. Jambhale, Jimmy A. Guo, Patrick Z. Yu, Tyler Jacks, François Aguet, Daniel Y. Kim, Harshabad Singh, Hannah I. Hoffman, Brenton R. Paolella, Maryann Zhao, William L. Hwang, Steven I. Wang, Andrew J. Aguirre, John M. Krill-Burger, Westley W. Wu, Kristen E. Lowder, James M. McFarland, Tobiloba E. Oni, Aviv Regev, Gad Getz, Peter Chen, Scott P. Ginebaugh
Publikováno v:
Cancer Research. 81:PR-006
Targeted therapies for molecularly-defined subtypes have led to immense clinical benefit for many cancer types but have generally not been successful for pancreatic cancer. Given that the mainstay of treatment remains multi-agent chemotherapy with FO